Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cytomx Thera (CTMX)
Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,766
  • Shares Outstanding, K 66,339
  • Annual Sales, $ 53,160 K
  • Annual Income, $ -99,320 K
  • 60-Month Beta 0.65
  • Price/Sales 2.10
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CTMX with:

Options Overview Details

View History
  • Implied Volatility 143.96% ( -38.00%)
  • Historical Volatility 45.17%
  • IV Percentile 57%
  • IV Rank 11.73%
  • IV High 946.43% on 07/29/22
  • IV Low 37.31% on 07/21/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 56
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 2,504
  • Open Int (30-Day) 3,443

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.19
  • Number of Estimates 6
  • High Estimate -0.14
  • Low Estimate -0.39
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +48.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6400 +4.27%
on 05/31/23
1.9500 -12.31%
on 05/23/23
+0.0100 (+0.59%)
since 05/05/23
3-Month
1.4300 +19.58%
on 03/28/23
2.2300 -23.32%
on 03/07/23
-0.4300 (-20.09%)
since 03/03/23
52-Week
1.1700 +46.15%
on 11/16/22
3.0200 -43.38%
on 01/09/23
-0.0700 (-3.93%)
since 06/03/22

Most Recent Stories

More News
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 68.75% and 5.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 1.7100 (-1.16%)
AGLE : 0.1290 (+0.78%)
CytomX Therapeutics: Q1 Earnings Snapshot

CytomX Therapeutics: Q1 Earnings Snapshot

CTMX : 1.7100 (-1.16%)
Codexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CDXS : 2.59 (-1.52%)
CTMX : 1.7100 (-1.16%)
Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Certara, Inc. (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CERT : 21.37 (-1.52%)
CTMX : 1.7100 (-1.16%)
Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CTMX : 1.7100 (-1.16%)
MYGN : 22.46 (-4.14%)
Walgreens, McCormick rise; Invesco Mortgage, CytomX fall

Stocks that traded heavily or had substantial price changes Tuesday: Walgreens, McCormick rise; Invesco Mortgage, CytomX fall

BABA : 84.40 (+0.15%)
IVR : 10.52 (-2.86%)
LYFT : 9.72 (+1.46%)
WBA : 31.25 (+0.19%)
CTMX : 1.7100 (-1.16%)
PVH : 76.96 (-0.88%)
AMZN : 125.30 (+0.85%)
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 1.7100 (-1.16%)
SPRO : 1.7700 (-2.75%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 24, 2023 – USA News Group  –  Treatments for various forms of breast cancer continue to evolve, with several new...

BCTX : 6.34 (+2.76%)
ONCY : 1.6400 (-4.65%)
ONC.TO : 2.15 (-5.70%)
CTMX : 1.7100 (-1.16%)
BCT.TO : 8.45 (+3.17%)
RLAY : 11.46 (-0.09%)
HOLX : 79.04 (-0.03%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

/PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in...

BCTXW : 2.65 (+4.12%)
ONC.TO : 2.15 (-5.70%)
BCT.TO : 8.45 (+3.17%)
ONCY : 1.6400 (-4.65%)
CTMX : 1.7100 (-1.16%)
BCTX : 6.34 (+2.76%)
RLAY : 11.46 (-0.09%)
HOLX : 79.04 (-0.03%)
Breast Cancer Treatment Options Evolved Over the Last 12 Months, Bringing More Hope for 2023

USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful...

BCTX : 6.34 (+2.76%)
ONCY : 1.6400 (-4.65%)
ONC.TO : 2.15 (-5.70%)
CTMX : 1.7100 (-1.16%)
BCT.TO : 8.45 (+3.17%)
RLAY : 11.46 (-0.09%)
HOLX : 79.04 (-0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 1.7698
2nd Resistance Point 1.7499
1st Resistance Point 1.7299
Last Price 1.7100
1st Support Level 1.6900
2nd Support Level 1.6701
3rd Support Level 1.6501

See More

52-Week High 3.0200
Fibonacci 61.8% 2.3133
Fibonacci 50% 2.0950
Fibonacci 38.2% 1.8767
Last Price 1.7100
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar